In a new paper just published in eClinicalMedicine, part of the Lancet group, we discuss, together with Sahar van Waalwijk, the fascinating consequences of three trials that all studied PARP (Poly (ADP-ribose) Polymerase)-inhibitors (PARPi) in combination with androgen receptor pathway inhibitors (
Good work, thank you. In the real world, do PARPs have any real benefit? (not being skeptical, just I don't hear good things in just about any indication)
The repeated design of clinical trials with suboptimal control arms is concerning and may exaggerate the effect of the drug(s) under study.
Good work, thank you. In the real world, do PARPs have any real benefit? (not being skeptical, just I don't hear good things in just about any indication)